Vosevi (sofosbuvir/velpatasvir/voxilaprevir) — Blue Cross Blue Shield of Illinois
Hepatitis C genotype 1, 2, 3, 4, 5, or 6, previously treated with specific HCV regimens
Initial criteria
- Patient previously treated with an HCV regimen containing an NS5A inhibitor (e.g., daclatasvir, elbasvir, ledipasvir, ombitasvir, velpatasvir) OR sofosbuvir without an NS5A inhibitor
- Without cirrhosis or with compensated cirrhosis (Child-Pugh A)
- For genotype 1a or 3, previously treated with sofosbuvir without an NS5A inhibitor
- Duration 12 weeks per FDA labeling
Approval duration
as per Table 9 (12 weeks typical)